Genentech, Inc.

Antabio Sas

Chiesi Farmaceutici S.p.a.

F. Hoffmann-la Roche Ag

Almac Discovery Limited

Rqx Pharmaceuticals, Inc.

Toby Jonathan Blench

Richard Leonard Elliott

Janusz Jozef Kulagowski

Stephen Colin Price

Jonathan Mark Sutton

Thomas David Pallin

David Edward Clark

Jun Liang

Steven R Magnuson

Robert Andrew Heald

Carmelida Capaldi

Simon Charles Goodacre

Vickie H Tsui

Karen Williams

Christine Edwards

Timothy Harrison

Andrew Madin

Bryan K Chan

Hazel Joan Dyke

Jacob Bradley Schwarz

Birong Zhang

BinQing Wei

Timothy Heffron

James John Crawford

Prasuna Paraselli

Sushant Malhotra

Emanuela Gancia

Emily J Hanan

Craig Stivala

Calum MacLeod

Michael Lainchbury

Terry Aaron Panchal

Cuong Q Ly

Calum Macleod

Michael F T Koehler

Simon Leiris

Martin Everett

Nicolas Sprynski

Andrew Peter Cridland

Timothy Colin Hancox

Frank Burkamp

Peter Andrew Smith

Elsa Amandine Dechaux

Lilha Beyria

Yingjie Lai

Neil Anthony Pegg

Colin O'Dowd

Matthew W Cartwright

Tucker Curran Roberts

David Thomas Davies

James Samuel Shane Rountree

Yongsheng Chen

Mandy Christine Beswick

Huiyong Hu

Charles Ellwood

Graham Peter Trevitt

Lixin Zhang

Zhiyong Yu

Sumita Bhattacharyya

Phillip Smith

Mark Peter Bell

Jahusz Jozef Kulagowski

Michael Steven Bodnarchuk

Robert I Higuchi

Calum McCleod

Paul Colin Michael Winship

The invention relates to an indane compound according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, L, n and p are as defined herein. The compounds are useful for treating antibacterial infection either as stand-alone antibiotics, or in combination with further antibiotics.

Indane derivatives for use in the treatment of bacterial infection

Spirocyclic 2,3-dihydro-7-azaindole compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the spirocyclic 2,3-dihydro-7-azaindole compounds.

Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof

The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R, R, R, n, R, p, q, L, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions. 

Chemical compounds as antibiotics

The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R, R, Rand Rare defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy. 

Pyrazolopyridine compounds, compositions and methods of use

Compounds of formula (I): are useful as inhibitors of human neutrophil elastase.

Compounds

Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R, R, Rand Rare defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I. 

Azabenzothiazole compounds, compositions and methods of use

The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.

Pharmaceutical compounds

Thiazolopyrimidine compounds of formula I, where W represents a thiazole ring, selectively inhibit the p110 delta subtype of PI3 Kinase (PI3K), and are useful for treating diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders. 

Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase

Thiazolopyrimidines of formula (I): wherein W represents a thiazole ring; Rand Rform, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is a ring system; m is 0, 1 or 2; Ris H or C-Calkyl; and Ris an indole group which is unsubstituted or substituted; and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110&#x3b4; isoform, which is a class Ia PD kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders. 

Growing community of inventors

Harlow, United Kingdom

Toby Jonathan Blench